FDA warned Workswell Group that its MEDICAS thermal camera was sold in the U.S. for COVID-19 screening without FDA approval.
What happened
FDA reviewed Workswell's website and social media pages on February 19, 2021, and found the MEDICAS thermal camera offered for sale in the United States. The pages said the camera could detect viral diseases including SARS-CoV2 and diagnose abnormal temperatures, and could scan unlimited people at once. FDA said the product was sold without marketing approval, clearance, or authorization.
What FDA found
The MEDICAS is offered for sale in the United States without FDA marketing approval, clearance, or authorization.
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The company did not have an approved premarket approval application or an investigational device exemption for the device.
Section 515(a), 21 U.S.C. § 360e(a); Section 520(g), 21 U.S.C. § 360j(g)FDA calls the product misbranded because the company did not notify FDA of its intent to market it, as required by the 510(k) process.
Section 502(o), 21 U.S.C. § 352(o); Section 510(k), 21 U.S.C. § 360(k)FDA said introduction or delivery of the product into interstate commerce is prohibited.
Section 301(a), 21 U.S.C. § 331(a)
What FDA wants
Within 48 hours, email COVID-19-Task-Force-CDRH@fda.hhs.gov with the steps taken to address the violations, how the company will prevent them from recurring, and supporting documents. If the company cannot act completely within 48 hours, it must state why and give a time when it will; if it believes the product is not in violation, it must include its reasoning and supporting information.
Who should pay attention
- distributors and resellers of thermal screening cameras
- venues using temperature screening for entry
- buyers of COVID-19-related medical devices
This is a summary. Read the original letter on fda.gov.